ESTRO 2025 - Abstract Book

S1449

Clinical - Lung

ESTRO 2025

Conclusion: In this study, incidence and severity of aRP in patients treated with TRT after ICI was higher than expected according to pre-ICI defined dose constraints (QUANTEC).

Keywords: Immunotherapy, radiation pneumonitis

4610

Digital Poster Survival outcomes before and after FDA approval of atezolizumab in extensive-stage small cell lung cancer: A SEER database analysis Ahmed Salem 1,2 , Ghena Shahwan 3 , Zaid Al-farra 3 , Fanar Al-Samarat 3 1 Department of Anatomy, Physiology and Biochemistry, The Hashemite University, Zarqa, Jordan. 2 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 3 Faculty of Medicine, The Hashemite University, Zarqa, Jordan Purpose/Objective: The IMpower133 published in 2018 demonstrated the survival advantage atezolizumab in combination with chemotherapy in extensive-stage small-cell lung cancer (ES-SCLC) (1). The US FDA issued approval for use of atezolizumab in March 2019. We investigated the effect of this approval on overall survival (OS) of ES-SCLC patients